Item 1.01 Entry into a Material Definitive Agreement.

On January 14, 2020, bluebird bio (Switzerland) GmbH, a wholly-owned subsidiary of bluebird bio, Inc. ("bluebird") and SAFC Carlsbad, Inc. ("SAFC") entered an amendment (the "Amendment") to the Clinical and Commercial Supply Agreement, dated as of November 27, 2017, for the production of lentiviral vector used in the manufacture of bluebird's drug product and drug product candidates (the "Agreement"), extending the term of the Agreement and modifying the production capacity and purchase commitments applicable to certain periods during the term.

The foregoing description of the terms of the Amendment does not purport to be complete, and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
   Exhibit                                             Description
     No.
     10.1        †      Amendment No. 2 to Clinical and Commercial Supply Agreement Viral Vector
                      Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad,
                      Inc.  .
     104              Cover Page Interactive Data File (embedded within the Inline XBRL document)

             † Certain portions of the exhibit (indicated by asterisks) have been omitted pursuant
               to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material
               and (ii) would likely cause competitive harm to bluebird if publicly disclosed.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses